1783 — Maxigen Biotech Income Statement

0.000.00%

Last trade - 00:00

Consumer DefensivesBalancedSmall CapHigh Flyer

Annual income statement for Maxigen Biotech, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	512	604	622	681	812
Cost of Revenue
Gross Profit	261	374	424	483	564
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Total Operating Expenses	422	476	472	501	551
Operating Profit	89.9	129	150	180	261
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	97.5	166	193	226	305
Provision for Income Taxes
Net Income After Taxes	87.7	139	166	190	265
Net Income Before Extraordinary Items
Net Income	87.7	139	166	190	265
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	87.7	139	166	190	265
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1.04	1.55	1.86	2.12	2.94
Dividends per Share